Connect your AI

10x Genomics, Inc. TXG Issuance of common stock for the acquisition of Ansys

Issuance of common stock for the acquisition of Ansys at other companies

Twist Bioscience CorporationTWST

——

Other financials

Income statement

Revenue$150.8M-2.6%

Gross profit$106.2M+0.7%

Operating income-$17.0M+56.7%

Net income-$13.5M+60.8%

EPS (diluted)-$0.10+64.3%

Balance sheet

Cash & equivalents$490.3M+30.0%

Total debt$81.4M+1.6%

Total equity$814.3M+15.2%

Total assets$1.0B+12.4%

Cash flow

Operating cash flow$26.1M-24.0%

CapEx$1.6M-15.6%

Free cash flow$24.5M-24.4%

Valuation

Market cap$4.41B+154%

Enterprise value$4B+199%

P/S6.9×+4.1×

Profitability

Gross margin69.6%+1.2pp

Operating margin-6.1%-2.7pp

Net margin-3.5%-1.6pp

FCF margin19.1%—

Returns & leverage

Return on equity-3%-1.4pp

Debt / equity0.1×0.0×

Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockIssued1.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s issuance of common stock for the acquisition of ansys.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is 10x Genomics, Inc.'s issuance of common stock for the acquisition of ansys?: 10x Genomics, Inc. (TXG) reported issuance of common stock for the acquisition of ansys of $8.7M in Q1 2026.